Why the study?
Does platelet depletion with specific antidog platelet antiserum reduce infarct size in an occlusion-reperfusion model of myocardial ischemia in anesthetized dogs?
Does platelet depletion with specific antidog platelet antiserum reduce infarct size in an occlusion-reperfusion model of myocardial ischemia in anesthetized dogs?
Platelet depletion does not reduce infarct size in a canine model of ischemia-reperfusion, suggesting platelets do not directly contribute to the extent of myocardial damage in this setting.
Answers are grounded in this paper and cite their sources.
Does not support platelet depletion to limit infarct size; leaves open platelets' role in human ischemia-reperfusion injury.
The formation of platelet aggregates and release of platelet-derived vasoactive mediators have been suggested to aggravate ischemic myocardium. The contribution of platelets to myocardial damage induced by 90-min occlusion and 5-h reperfusion in chloralose-anesthetized dogs was assessed after depletion of platelets with specific antidog platelet antiserum. Dogs treated with antiplatelet antiserum showed greater than 90% reduction in circulating platelets and serum TxB2 levels, but showed no reduction in infarct size (58 +/- 3 vs. 51 +/- 3% of risk area for control and thrombocytopenic dogs, respectively). Platelet depletion had no hemodynamic effect during the occlusion or reperfusion phases, nor reduced the incidence of arrhythmias. These results indicate that platelet aggregates or platelet-derived mediators do not contribute directly to the extent of damage in this occlusion-reperfusion model of myocardial ischemia.
No takes yet. Share an insight, caveat, or question.
Mullane et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: